logo

Press Releases

    • 24 JUN 2015

    PharmaCyte Biotech Enters Into Research and Consulting Agreements With University of Technology Sydney

    SILVER SPRING, Md., June 23, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has signed a major Research Services Agreement and an important Consulting Contract with the University of Technology

    Read more →
    • 17 JUN 2015

    Novel Pancreatic Cancer Drug May also Combat Malignant Ascites

    Treatment Being Studied Involves a Combo of Low-Dose Cancer Prodrug Ifosfamide and Cell-in-a-Box Capsules

      SILVER SPRING, Md.—Ascites, which is the buildup of fluid in the abdominal cavity, is called malignant ascites when caused by cancer and accounts for 10 percent of people with ascites. Malignant ascites appears most often in people with breast,

    Read more →
    • 16 JUN 2015

    PharmaCyte Biotech Showcasing Technology and Treatments at 2015 BIO International Convention

    SILVER SPRING, MD, June 16, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, JD, and its Chief Operating Officer, Gerald W. Crabtree, Ph.D.,

    Read more →
    • 16 JUN 2015

    PharmaCyte Biotech Advances Cannabinoid Research with Schedule 1 License

    SILVER SPRING, MD, June 15, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its research partner, the University of Northern Colorado (UNC), successfully obtained a Schedule 1 license from the

    Read more →
    • 12 JUN 2015

    PharmaCyte Biotech’s Diabetes Treatment to Be Presented at Austrodrugs 2015

    SILVER SPRING, Md., June 12, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that the company’s diabetes treatment and the research program of its international Diabetes Consortium will be presented at the

    Read more →
    • 10 JUN 2015

    PharmaCyte Biotech Officers to Attend 2015 BIO International Convention

    SILVER SPRING, Md., June 10, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, JD, and its Chief Operating Officer, Gerald W. Crabtree, Ph.D., will

    Read more →
    • 09 JUN 2015

    PharmaCyte Biotech’s Contract Research Organization Voted Australia’s Favorite CRO for 2015

    SILVER SPRING, MD, June 9, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that Clinical Network Services (CNS), the Contract Research Organization (CRO) chosen by PharmaCyte Biotech to prepare for and

    Read more →
    • 26 MAY 2015

    PharmaCyte Biotech to Attend Annual Meeting of the American Society of Clinical Oncology

    SILVER SPRING, Md., May 26, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today announced that its Chief Executive Officer Kenneth L. Waggoner and Chief Operating Officer Dr. Gerald W. Crabtree will attend the

    Read more →
    • 20 MAY 2015

    New Advances in Diabetes Treatment: Insulin-Producing Cells That Could Replace Injections

    Dr. Gerald Crabtree, Chief Operating Officer and Director at PharmaCyte Biotechnology, a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box joins eHealth Radio and the Diabetes and Health News Channels.Listen to interview with host Eric Michaels and guest Dr. Gerald Crabtree discuss the

    Read more →
    • 20 MAY 2015

    PharmaCyte Biotech Creates Faster Path to the Clinic for Company’s Diabetes Treatment

    NEW YORK, NY–(Marketwired – May 20, 2015) – PharmaCyte Biotech (PMCB) has managed to do something that is rarely done in science — bring together an international group of leading experts to work on one project. The project that is drawing their interest is PharmaCyte Biotech’s diabetes treatment and getting that treatment into the hands

    Read more →